In this context, the ‘non-classical’ DHFR inhibitors provide a valuable opportunity to cope with several melanoma-specific resistance mechanisms that made them insensitive to the classical inhibitors of this enzyme and others involved in the metabolic pathway of the folate cycle. The gene discussed is DHFR; the disease is melanoma.